{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-032986","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.763535+00:00","generated_at":"2026-06-18T00:53:03.534579+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Liquidia reports FY 2022 revenue $15.9M, net loss $41.0M; YUTREPIA launch path by H1 2024","bullets":["Revenue $15.9M (+23% YoY); net loss $41.0M ($0.67/share) vs $34.6M loss in 2021.","Legal resolution for YUTREPIA expected late 2023 to H1 2024; PTAB invalidated '793 patent.","Cash $93.3M at Dec 31, 2022; HCRx revenue interest financing up to $100M ($32.5M funded).","New CEO, CMO, Head of Sales; collaboration with Mainbridge for repurposed infusion pump.","Amended Sandoz promotion agreement extends to 2032; pump repair costs split equally."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-032986","json":"https://secwatch.observer/filing/0001104659-23-032986.json","markdown":"https://secwatch.observer/filing/0001104659-23-032986.md","text":"https://secwatch.observer/filing/0001104659-23-032986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923032986/0001104659-23-032986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923032986/tm239718d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:53:03.534579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c08577426808632c984bb4ed169ea1f5d365a6b","claim":"Liquidia Corp reported financial results for full year ended December 31, 2022.","evidence_excerpt":"issued a press release announcing its financial results for the full year ended December 31, 2022, and also provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923032986/0001104659-23-032986-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eddf473b3eae62a46ea9d5e614dc68fa5fea479c","claim":"Liquidia Corp amended Fourth Amendment to Promotion Agreement with Sandoz Inc. (effective 2023-03-10).","evidence_excerpt":"On March 10, 2023, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Fourth Amendment to Promotion Agreement (the “Fourth Amendment”) with Sandoz Inc. (“Sandoz”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923032986/0001104659-23-032986-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Sandoz Inc."},{"label":"Effective","value":"2023-03-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}